GLP-1 Therapy (Ozempic, Wegovy, Mounjaro, Zepbound): What Patients Should Know

Many patients searching for medical weight loss information encounter brand names such as Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. These medications belong to a class of prescription treatments commonly referred to as GLP-1–based therapies and are used under medical supervision for selected patients as part of a comprehensive weight management plan.

This article explains what GLP-1 therapy is, how these medications work, who may be eligible, and what to expect from treatment—using clear, evidence-based, and medically appropriate information.

 

 

 

 

 

 

 

What Is GLP-1 Therapy?

GLP-1 therapy refers to prescription medications that act on hormones involved in appetite regulation and metabolism. GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the body that plays a role in:

• appetite signaling

• feelings of fullness

• gastric emptying

• blood glucose regulation

Some newer medications also act on additional metabolic pathways. Brand names commonly associated with this class include Ozempic®, Wegovy®, Mounjaro®, and Zepbound®, among others.

These medications were initially developed for diabetes management and are now also used, when clinically appropriate, in medical weight management programs. They are prescription-only medications and must be assessed, prescribed, and monitored by a qualified healthcare professional.

​​

​

​

​

​

​

​

​

​

​

 

 

 

 

 

How Do Medications Like Ozempic, Wegovy, Mounjaro, and Zepbound Support Weight Management?

GLP-1–based therapies may support weight management by:

• reducing appetite and hunger cues

• increasing satiety after meals

• helping regulate eating patterns

• supporting portion control

It is important to note that responses vary between individuals, and no specific amount of weight loss can be guaranteed. These medications are most effective when used as part of a broader care plan that includes:

• nutrition guidance

• lifestyle and behaviour support

• regular medical follow-up

Medication alone is not considered sufficient treatment.

​

 

 

 

 

 

 

 

 

 

Are These Medications the Same?

Although often discussed together, Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are not identical. They may differ in:

• approved indications

• dosing schedules

• mechanisms of action

• insurance coverage and availability

A healthcare provider determines which option, if any, may be appropriate based on an individual’s medical history, goals, and risk profile. Patients should not switch or start medications without medical guidance.

​

Who May Be Considered for GLP-1 Therapy?

GLP-1 therapy may be considered for adults who:

• have obesity or excess weight affecting health

• have struggled to achieve or maintain weight loss through lifestyle changes alone

• may have weight-related conditions such as prediabetes, type 2 diabetes, or hypertension

Eligibility is determined only after a comprehensive medical assessment. These medications are not appropriate for everyone, and certain medical conditions or risk factors may exclude their use.

​

What Happens Before Starting Treatment?

Before prescribing medications such as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®, a healthcare provider will conduct a structured assessment that may include:

• review of medical and weight history

• discussion of goals and expectations

• evaluation of current medications

• assessment of risks and benefits

• review of laboratory results when clinically indicated

Only after this assessment can a treatment decision be made.

​

Ongoing Monitoring and Follow-Up

GLP-1 therapy requires ongoing medical supervision. During treatment, follow-up visits allow providers to:

• monitor response and tolerance

• adjust dosing as needed

• manage potential side effects

• support long-term weight management strategies

Regular follow-up is an essential part of safe and effective care.

​

 

 

 

 

 

 

 

 

Potential Side Effects and Safety Considerations

As with all prescription medications, GLP-1–based therapies may cause side effects. These vary by individual and may be more noticeable during dose adjustments.

Before starting therapy, patients receive education about:

• possible side effects

• when to seek medical advice

• how treatment will be monitored

Patients are encouraged to report any symptoms or concerns promptly.

​

GLP-1 Therapy Is Part of a Comprehensive Care Plan

At Edgemont Weight Clinic, medications such as Ozempic®, Wegovy®, Mounjaro®, or Zepbound® are never offered as standalone solutions. When prescribed, they are integrated into a medically supervised program that may include:

• personalized nutrition planning

• lifestyle and behaviour support

• body composition and progress tracking

• transition and maintenance planning

The focus is on safe, realistic, and sustainable weight management, not rapid or guaranteed outcomes.

​

Important Medical Disclaimer

Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are prescription medications and are not suitable for everyone. Treatment decisions are made on an individual basis following a medical assessment. Weight loss outcomes vary, and no specific results can be guaranteed.

This information is provided for educational purposes only and does not replace medical advice. Patients should consult a qualified healthcare professional to determine whether GLP-1 therapy is appropriate for them.

​

Considering GLP-1 Therapy?

If you are researching Ozempic®, Wegovy®, Mounjaro®, or Zepbound® and want to understand whether GLP-1 therapy may be appropriate for you, the first step is a medical consultation.

A structured assessment allows your care team to review your health history and discuss evidence-based treatment options safely and responsibly.